Syndax Pharmaceuticals (SNDX) investor relations material

Company overview and strategic priorities

• Positioned for strong performance in 2025 and 2026, driven by two key programs, Revuforj and Niktimvo, both showing robust sales and franchise growth.

• Focused on maintaining leadership in menin inhibition and GVHD, with ongoing execution and data generation to support physician adoption.

• Key challenge is to continue execution and expand leadership positions, supported by new clinical data.

• Emphasis on delivering shareholder value through data-driven expansion and broader patient reach.

Clinical data highlights and upcoming presentations

• Revuforj post-maintenance therapy data from MD Anderson shows 90% one- and two-year OS rates, outperforming historical controls (50-60%).

• Cumulative incidence of relapse is three times lower than historical controls, supporting use post-transplant.

• Data reproducibility confirmed at other major centers, with similar OS rates and event-free survival of 84% at one year.

• Ongoing randomized controlled study (MAINTAIN) with Dana-Farber to further validate post-transplant maintenance.

Safety, dosing, and management strategies

• Thrombocytopenia and neutropenia are managed with dose modifications and G-CSF; ongoing phase I study aims to optimize management.

• Flexible dosing schedules allow for individualized patient management post-engraftment.

• Phase I data on dosing and cytopenia management to be presented later this year.